header-logo header-logo

28 February 2014 / Sarah Moore
Issue: 7596 / Categories: Features , Regulatory
printer mail-detail

A bitter pill?

What impact will the new European Medical Device Regulations have on UK medicine, asks Sarah Moore

At the end of last year, after a year of fierce lobbying by patient groups and manufacturers alike, the new European Medical Device Regulations were finally submitted to the European Parliament and Council for debate and member state approval. When implemented, these new regulations will change legislation that has remained largely untouched for over 20 years.

Ongoing, high profile, prosthetic hip and breast implant litigation has played a key role in galvanising this change. However, exactly what impact these proposed regulatory changes will have, both for patient safety and product litigation in the UK remains to be seen.

EUCOMED, the organisation which speaks for European medical device manufacturers, has warned that the new regulations will stifle innovation and slow down the release of novel products into the market. For product liability lawyers, and others dealing with the after-effects of “novel” products, such as the ASR hip prosthesis, this change in pace has the potential at least to better

If you are not a subscriber, subscribe now to read this content
If you are already a subscriber sign in
...or Register for two weeks' free access to subscriber content

MOVERS & SHAKERS

Foot Anstey—Jasmine Olomolaiye

Foot Anstey—Jasmine Olomolaiye

Investigations and corporate crime expert joins as partner

Fieldfisher—Mark Shaw

Fieldfisher—Mark Shaw

Veteran funds specialist joins investment funds team

Taylor Wessing—Stephen Whitfield

Taylor Wessing—Stephen Whitfield

Firm enhances competition practice with London partner hire

NEWS
Could an online LLM in Commercial and Technology Law expand your career options?
The controversial Courts and Tribunals Bill has passed its second reading by 304 votes to 203, despite concerted opposition from the legal profession
The presumption of parental involvement is to be abolished, the Lord Chancellor David Lammy has confirmed
A highly experienced chartered legal executive has been prevented from representing her client in financial remedies proceedings, in a case that highlights the continued fallout from Mazur
Plans to commandeer 50%-75% of the interest on lawyers’ client accounts to fund the justice system overlook the cost and administrative burden of this on small and medium law firms, CILEX has warned
back-to-top-scroll